Emtricitabine
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
Emtricitabine: From HIV-1 Infection to Simian Immunodeficiency Virus (SIV) Infection
One-Sentence Summary
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) established internationally as an antiretroviral for HIV-1 infection, most often as part of fixed-dose combinations such as Truvada and Descovy. The TxGNN model’s top prediction points to Simian Immunodeficiency Virus (SIV) Infection, an animal (macaque) disease model rather than a human indication, supported by 2 clinical trials (both graded low relevance) and 20 publications (mostly non-human primate PrEP/pathogenesis studies). This evidence pack does not currently support a viable human repurposing candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no UK marketing authorisation record); Emtricitabine is internationally established as an NRTI for HIV-1 infection |
| Predicted New Indication | Simian Immunodeficiency Virus Infection (animal/macaque disease model) |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data was not available in this evidence pack (flagged as a data gap). Based on established pharmacological knowledge, Emtricitabine is a cytidine nucleoside analogue that inhibits HIV reverse transcriptase, and it is typically co-formulated with tenofovir as part of antiretroviral treatment or pre-exposure prophylaxis (PrEP) regimens for HIV-1.
The mechanistic rationale for the TxGNN prediction is that SIV, like HIV, is a lentivirus with a highly homologous reverse transcriptase, so a reverse-transcriptase inhibitor active against HIV would plausibly also inhibit SIV replication. Indeed, emtricitabine/tenofovir combinations are already the standard antiretroviral regimen used in macaque SIV/SHIV challenge studies.
However, this mechanistic plausibility does not translate into a genuine human repurposing opportunity: SIV infection is a disease of non-human primates used as a laboratory model for HIV research, not a condition that occurs in human patients. The second-ranked prediction (feline immunodeficiency virus, FIV) is similarly a veterinary indication in cats, with only weak, indirect evidence for efficacy against the FIV reverse transcriptase. The third-ranked prediction (a rare inherited neurodevelopmental disorder) has no supporting clinical trials or literature and no identifiable biological link to an NRTI mechanism — this is most likely a false positive arising from proximity in the model’s embedding space rather than a real signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00863668 | N/A | Withdrawn (enrolment 0) | 0 | Study of HIV decay kinetics with raltegravir in humans, referencing comparable SIV decay kinetics in macaques; not an emtricitabine intervention study and did not enrol any participants. |
| NCT03577782 | Phase 1/2 | Unknown | 12 | Vedolizumab combined with antiretroviral therapy in HIV-infected humans aiming at virological remission; emtricitabine is not the primary intervention and the trial does not involve SIV. |
Both trials were flagged as low relevance (Grade C) — they were retrieved on keyword overlap (“immunodeficiency virus”) rather than genuine relevance to emtricitabine as a treatment for SIV infection. No trial in this evidence pack directly tests emtricitabine against SIV or any equivalent human indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20874040 | 2010 | RCT (human, systemic PrEP) | Pharmacotherapy | Review/RCT evidence on systemic pre-exposure prophylaxis for HIV infection in humans, underpinning the PrEP rationale later tested in animal SIV/SHIV models. |
| 31362305 | 2019 | RCT (human PrEP) | J Infect Dis | Oral tenofovir alafenamide/emtricitabine combination evaluated against vaginal SHIV infection in macaques, informing human PrEP regimen design. |
| 39632836 | 2024 | Animal model (macaque) | Nature Communications | Emtricitabine/tenofovir alafenamide plus long-acting cabotegravir/rilpivirine tested for SHIV remission in macaques with early treatment initiation. |
| 27465645 | 2016 | Animal model (macaque) | J Infect Dis | Oral emtricitabine/tenofovir alafenamide chemoprophylaxis protected macaques from rectal SHIV infection. |
| 26743846 | 2016 | Animal model (macaque) | J Infect Dis | Emtricitabine/tenofovir disoproxil fumarate prevented vaginal SHIV infection in macaques co-infected with Chlamydia and Trichomonas. |
| 23633402 | 2013 | Animal model (macaque) | J Infect Dis | Oral emtricitabine/tenofovir disoproxil fumarate protected macaques against a tenofovir-resistant (K65R) SHIV strain. |
| 18216122 | 2008 | Animal model (SIV dynamics) | J Virology | Antiretroviral therapy including emtricitabine and tenofovir used to study SIVagm dynamics in African green monkeys. |
| 12021341 | 2002 | Animal model (SIV virology) | J Virology | Emtricitabine (and lamivudine) therapy in SIV-infected macaques led to emergence of the M184V resistance mutation, mirroring human HIV resistance patterns. |
| 29788316 | 2018 | Animal/ex vivo (rectal challenge) | J Infect Dis | Vaginally administered emtricitabine/tenofovir gel evaluated against repeated rectal SHIV exposure in macaques. |
| 24914761 | 2014 | Animal model (vaccine + PrEP) | AIDS Res Hum Retroviruses | Combined HIV vaccine and partially protective oral PrEP (including emtricitabine) prevented SHIV infection in macaques. |
All identified literature relates to animal (macaque) models of SIV/SHIV used as HIV research surrogates, or to human PrEP studies for HIV-1 itself — none constitutes clinical evidence of emtricitabine efficacy in a human disease population corresponding to SIV infection.
UK Market Information
No marketing authorisation is recorded in this evidence pack (market status: Not marketed; 0 licenses on file). Emtricitabine is internationally marketed as part of combination antiretroviral products (e.g., Truvada, Descovy, Atripla); confirmation of current UK/MHRA licensing status should be obtained directly from the MHRA product register and the BNF before any further evaluation.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale:
- None of the three top TxGNN-predicted indications constitutes a valid human repurposing target: SIV infection and feline immunodeficiency syndrome are animal/veterinary disease models rather than human conditions, and the third prediction (a rare neurodevelopmental disorder) has no supporting evidence or plausible mechanistic link, indicating a likely false positive.
- The associated clinical trial evidence is either graded as irrelevant (keyword mismatch) or drawn from non-human primate research, and no direct human clinical evidence supports a genuinely new indication.
To proceed, the following is needed:
- Resolve the Blocking data gap (DG001): TFDA/MHRA product label warnings and contraindications, required before any safety pre-screening (S1) can begin.
- Resolve the High-severity data gap (DG002): confirmed mechanism-of-action data from DrugBank to properly assess mechanistic relevance of any future candidate indication.
- Re-run or filter the TxGNN prediction set to exclude non-human disease ontology terms, and review lower-ranked candidates for genuine human-relevant indications.
- Confirm current UK marketing authorisation status directly with the MHRA, since this evidence pack shows no licences on file.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.